Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission (CR)

NCT00003991 is registered in ClinicalTrials.gov with Maxim Pharmaceuticals as lead sponsor.

NCT NCT00003991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission (CR)
Lead sponsor
Maxim Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
July 31, 1998
Completion date
August 31, 2011
Enrollment
360 (estimated)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia